Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 2Urinary Bladder Neoplasms 1Malignant Solid Neoplasm 1Kidney Neoplasms 1

Interventions

aldesleukin 24Cyclophosphamide 14Interferon-alpha 10fludarabine 8fludarabine phosphate 7Interleukin-2 6Chemotherapy, Adjuvant 6sargramostim 5Neoadjuvant Therapy 5Fluorouracil 4Vincristine 3Sunitinib 3Magnetic Resonance Spectroscopy 3Dactinomycin 3Carboplatin 3Bevacizumab 3Amplified Fragment Length Polymorphism Analysis 3vandetanib 2valspodar 2tanespimycin 2ixabepilone 2carboxyamido-triazole 2bryostatin 1 2Vinblastine 2Thalidomide 2Temozolomide 2Sorafenib 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Muromonab-CD3 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Kidney Neoplasms × Ferrosoferric Oxide × Clear all
NCT02141490 2019-09-06

Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
43 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms, Kidney Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡